Shanghai Allist Pharmaceuticals

688578.SSPhase 2

Shanghai, ChinaFounded 2004allist.com.cn

Shanghai Allist Pharmaceuticals is a publicly-traded Chinese biopharmaceutical company that develops and commercializes innovative therapeutic solutions across multiple disease areas including cardiovascular and metabolic disorders. With its listing on the Shanghai Stock Exchange under ticker 688578.SS and a market valuation of approximately $5.9 billion, the company represents a significant player in China's growing biotechnology sector. Allist focuses on advancing novel drug candidates through clinical development while building a robust pipeline to address unmet medical needs in both domestic and international markets.

Market Cap

$5.9B

Founded

2004

Focus

Biotech

688578.SS · Stock Price

USD 90.23+65.93 (+271.32%)

Historical price data

AI Company Overview

Pipeline Snapshot

2 drugs in pipeline

Drug	Indication	Stage	Watch
Furmonertinib + Anlotinib	Non-Small-Cell Lung Cancer	Phase 2
TKI	Lung Cancer (NSCLC)	Pre-clinical

Funding History

Total raised: $355M

IPO$300MUndisclosedAug 20, 2020

Series B$40MHillhouse CapitalMar 15, 2020

Series A$15MQiming Venture PartnersMay 15, 2018

Opportunities

Shanghai Allist is well-positioned to capitalize on China's growing pharmaceutical market, supportive government policies for innovative drug development, and increasing healthcare spending from an aging population.

The company's public listing provides access to capital markets for funding clinical development and potential international expansion opportunities.

Risk Factors

Key risks include the inherent uncertainties of drug development with high clinical trial failure rates, intense competition in pharmaceutical markets, and regulatory risks from potential changes in approval processes.

The company also faces capital requirements for sustained clinical development and the challenge of achieving market access and reimbursement for its products.

Competitive Landscape

Allist competes in the highly competitive Chinese pharmaceutical market against both domestic innovative biotech companies and established international pharmaceutical giants. Differentiation will depend on pipeline strength, regulatory expertise, and the ability to successfully bring innovative therapeutics to market while navigating China's evolving healthcare landscape.

Publications

Patents

Pipeline